News

August 31, 2020August 31, 2020

Idhifa Combo Fails to Prolong Survival in Older Patients in Phase 3 Trial

News

Idhifa (enasidenib), given alongside best supportive care, failed to prolong overall survival of older adults with relapsed or refractory acute myeloid leukemia (AML) carrying a mutation in the IDH2 ... Read more

August 27, 2020August 27, 2020

Venclexta Plus Vidaza Increases AML Survival, Study Shows

News

Adding Venclexta (venetoclax) to treatment with Vidaza (azacitidine) significantly prolongs survival in people with acute myeloid leukemia (AML) who have not been treated before, a new study demonstrates. The ... Read more

August 20, 2020August 20, 2020

Phase 1 Trial for Potential Oral Therapy CB-5339 for Myeloid Cancers Doses First Patient

News

A Phase 1 clinical trial evaluating Cleave Therapeutics’ experimental oral therapy CB-5339 as a treatment for people with relapsed or refractory acute myeloid leukemia (AML) or intermediate- to high-risk myelodysplastic syndrome (MDS) ... Read more

August 6, 2020August 6, 2020

Biosight’s Less Toxic Chemo BST-236 Wins FDA Fast Track Status for AML

News

Biosight‘s BST-236 (aspacytarabine), a less toxic form of chemotherapy for acute myeloid leukemia (AML), has received fast track designation from the U.S. Food and Drug Administration (FDA) for patients ages ... Read more

July 30, 2020July 30, 2020

Trial of CPI-613 in Older AML Patients Moves Closer to 1st Interim Analysis

News

The Phase 3 trial testing Rafael Pharmaceuticals‘ CPI-613 (devimistat) as a treatment for relapsed or refractory acute myeloid leukemia (AML) has enrolled more than half of the participants needed ... Read more

July 23, 2020July 23, 2020

Blood Cancer Groups Unite to Award $6.75M to ‘Propel Discoveries’

News

A program created by three advocacy groups has awarded more than $6.75 million in multiyear grants to nine scientists whose work might drive a new generation of blood cancer ... Read more

July 20, 2020July 20, 2020

New Molecule Shows Promise as Potential Cancer Vaccine for AML

News

Australian scientists have created a promising new vaccine candidate against cancers that express the Wilms’ tumor 1 (WT1) gene. These include cancers of the blood, like acute myeloid leukemia (AML), ... Read more

July 16, 2020July 16, 2020

First Patient Dosed in Phase 1 Trial Testing Small Molecule Treatment CA-4948 for AML

News

The first patient has been dosed in a Phase 1 trial investigating the small molecule CA-4948 as a treatment for people with acute myeloid leukemia (AML) or high-risk myelodysplastic ... Read more

July 13, 2020July 13, 2020

Helsinn, Mei Pharma Stop Phase 3 Trial of Pracinostat-Vidaza Combo for AML

News

Helsinn and Mei Pharma have discontinued the Phase 3 trial that was investigating the safety and efficacy of a combination therapy of pracinostat and Vidaza (azacitidine) in newly-diagnosed patients ... Read more

July 9, 2020July 9, 2020

FDA Allows Human Trials of Aptose’s CG-806 Oral Compound for AML

News

The U.S. Food and Drug Administration (FDA) has granted Aptose Biosciences an investigational new drug (IND) allowance that will let the company begin a human Phase 1a/b clinical study ... Read more

Pin It on Pinterest